Ipamorelin binds GHSR-1a with a Ki of 1 to 3 nM, giving researchers a selective agonist that isolates ghrelin-receptor signaling. Researchers get clean Gq/11, PLC, IP3, Ca²⁺ coupling that drives pulsatile GH release from pituitary somatotrophs. Unlike GHRP-6 or hexarelin, it avoids CD36 and 5-HT engagement, so researchers skip the ACTH, cortisol, and prolactin confounds. In primary pituitary cells, it pushes GH ~8.2-fold over baseline. The mechanistic details below sharpen how this selectivity holds up.
Key Takeaways
- Ipamorelin is a selective GHSR-1a agonist with reported binding affinity (Ki) around 1 to 3 nM in research models.
- GHSR-1a activation triggers Gq/11-coupled signaling, activating phospholipase C, generating IP3, and releasing intracellular calcium.
- Selectivity isolates GHSR-1a signaling, avoiding ACTH, cortisol, and prolactin confounds seen with older GHRPs.
- Unlike hexarelin, ipamorelin shows no CD36 binding and only minimal 5-HT engagement compared with GHRP-6.
- In pituitary cells, ipamorelin drives GH secretion ~8.2-fold over baseline while keeping ACTH and prolactin near baseline.
What is Ipamorelin and how does it bind the GHSR
Ipamorelin is a synthetic pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH₂, that acts as a selective agonist at the growth hormone secretagogue receptor 1a (GHSR-1a), the same receptor endogenous ghrelin activates. It engages GHSR-1a on pituitary somatotroph cells with low-nanomolar affinity, reported Ki values around 1 to 3 nM depending on the source. Upon binding, it triggers a Gq/11-coupled signaling cascade: phospholipase C activation, IP3 generation, and intracellular calcium release, driving pulsatile growth hormone secretion in a dose-dependent manner. Downstream ERK1/2 phosphorylation occurs, with an EC₅₀ near 18 nM in GT1-7 hypothalamic neurons expressing endogenous GHSR-1a. This receptor-targeted profile isolates GHSR-1a-dependent signaling, distinguishing it from broader secretagogue effects and making ipamorelin a precise pharmacologic tool.
What is the growth hormone secretagogue receptor
The growth hormone secretagogue receptor 1a (GHSR-1a) is the molecular target that defines ipamorelin’s activity. GHSR-1a is the receptor that endogenous ghrelin activates in growth-hormone signaling research. Researchers find it expressed on pituitary somatotroph cells, where its activation drives pulsatile growth hormone release. It’s a G-protein coupled receptor, so when ipamorelin binds, researchers trigger a defined intracellular cascade rather than a diffuse response.
- Gq/11 coupling: activates phospholipase C, generating IP3 and releasing intracellular calcium.
- Somatotroph localization: concentrates GH-releasing activity at the pituitary, matching endocrine pulse patterns.
- Ghrelin identity: the same receptor endogenous ghrelin uses, letting researchers model ghrelin biology directly.
That mechanistic precision makes GHSR-1a a clean signaling anchor for research.
Why does Ipamorelin selectivity matter in research
Ipamorelin selectivity matters in research because it lets researchers attribute an effect to one signaling pathway instead of a tangle of confounders. Because ipamorelin acts as a selective GHSR-1a agonist, researchers can isolate ghrelin-receptor signaling from the ACTH, cortisol, and prolactin co-secretion that complicate older GHRPs. That matters when researchers are interpreting data: swine models show no significant ACTH or cortisol increase even at doses 200-fold above the GH-releasing ED50, and pituitary-cell summaries report ACTH at 0.8× and prolactin at 1.1× baseline. Since ipamorelin doesn’t meaningfully engage 5-HT subtypes or bind CD36, researchers eliminate appetite- and hexarelin-linked variables. This “clean” profile lets researchers map Gq/11, PLC, IP3, Ca²⁺ signaling and ERK1/2 phosphorylation to GHSR-1a activation with far greater confidence.
How is Ipamorelin studied in models
Ipamorelin is studied in models by tracking defined signaling endpoints across model systems, quantifying receptor engagement, downstream cascades, and hormone output against matched controls. Researchers anchor readouts to GHSR-1a activation, Gq/11 coupling, phospholipase C, IP3, and intracellular calcium release, then confirm selectivity by measuring off-target endocrine responses.
- Primary anterior pituitary cells: Ipamorelin drives GH secretion ~8.2-fold over baseline, while ACTH sits at 0.8× and prolactin at 1.1×, both nonsignificant.
- GT1-7 hypothalamic neurons: Endogenous GHSR-1a yields ERK1/2 phosphorylation with an EC₅₀ near 18 nM, versus GHRP-2’s ~6 nM.
- Selectivity frameworks: Researchers apply knockout, antagonist, and biased-agonist designs to isolate GHSR-1a-dependent signaling.
These approaches let researchers separate GH-axis effects from broader secretagogue activity precisely.
How does Ipamorelin binding compare to non-selective secretagogues
Ipamorelin’s binding profile diverges from non-selective secretagogues like GHRP-6 and hexarelin through its receptor selectivity. Researchers are looking at a compound that engages GHSR-1a with Ki values around 1 to 3 nM while avoiding off-target receptors that broaden earlier GHRPs’ effects. Ipamorelin doesn’t bind CD36, the receptor tied to hexarelin’s actions, and it doesn’t meaningfully engage 5-HT subtypes driving GHRP-6-type appetite signaling.
| Property | Ipamorelin | Non-selective GHRPs |
|---|---|---|
| GHSR-1a Ki | ~1 to 3 nM | Low-nanomolar |
| CD36 binding | None | Hexarelin engages |
| 5-HT engagement | Minimal | GHRP-6 active |
When researchers compare ERK1/2 signaling, ipamorelin’s EC₅₀ near 18 nM trails GHRP-2’s 6 nM, showing lower potency but cleaner receptor targeting overall.
How to source research-grade Ipamorelin
Research-grade ipamorelin comes from suppliers who verify the molecular identity researchers are actually buying: the pentapeptide Aib-His-D-2-Nal-D-Phe-Lys-NH₂. Researchers want documentation confirming sequence accuracy, since off-target contaminants can compromise GHSR-1a selectivity data. Reputable suppliers provide analytical certificates that let researchers correlate the compound with the low-nanomolar Ki values (roughly 1 to 3 nM) reported in the literature.
- Mass spectrometry confirmation matching the expected molecular weight of the intact pentapeptide sequence
- HPLC purity data (typically ≥98%) to minimize interference in ERK1/2 or GH-secretion assays
- Certificate of Analysis documenting identity, purity, and lot-specific results
Cross-check these against published receptor-binding parameters. If a supplier can’t verify sequence and purity, researchers can’t trust downstream selectivity measurements distinguishing GHSR-1a-dependent signaling from broader secretagogue effects.
Shop GH Secretagogues at Holas
From GHRP-2 to Ipamorelin to CJC-1295, comparing receptor selectivity requires research-grade peptides with verified purity. Holas supplies laboratory-grade Ipamorelin and CJC-1295 peptides, third-party tested and prepared for research use. Browse our shop or contact us to source the right peptides for the work.
Frequently Asked Questions
How Should Research-Grade Ipamorelin Be Stored and Reconstituted for Stability?
Researchers store lyophilized ipamorelin at -20°C, protected from light and moisture, where it stays stable for months to years. Reconstitute it with bacteriostatic or sterile water, adding the diluent slowly down the vial wall to avoid shearing the pentapeptide. Don’t vortex; swirl gently instead. Once reconstituted, researchers keep it at 2 to 8°C and use it within a few weeks, since aqueous solutions degrade faster through hydrolysis and aggregation.
What Is the Half-Life of Ipamorelin in Research Models?
Ipamorelin’s half-life is reported at roughly two hours in preclinical models, longer than many earlier GHRPs such as GHRP-6 and GHRP-2, which clear within about 15 to 60 minutes. This extended clearance window supports sustained GHS-R1a engagement and more prolonged pulsatile GH release before elimination. Because clearance varies with species, route, and assay conditions, pharmacokinetic parameters are typically verified against the specific model rather than assumed from a single reported figure.
Does Ipamorelin Show Desensitization With Repeated Exposure in Cell Assays?
Direct desensitization data for ipamorelin in repeated-exposure cell assays are limited, but the mechanism makes it plausible. Ipamorelin activates GHS-R1a through Gq/11, phospholipase C, and ERK1/2 signaling with an EC50 around 18 nM, and sustained agonism at G-protein-coupled receptors like GHS-R1a commonly drives receptor internalization and downstream desensitization. In practice, repeated or continuous GHS-R1a activation tends to attenuate signaling over time, whereas spaced, pulsatile exposure preserves responsiveness. Antagonist and biased-agonist designs are typically used to isolate whether repeated activation blunts GH-releasing responses in a given assay.
Are There Known Interactions Between Ipamorelin and GHRH in Experiments?
Yes. Ipamorelin and GHRH act synergistically in experimental models. Ipamorelin targets GHS-R1a while GHRH engages its own distinct receptor on somatotrophs, so the two activate parallel signaling pathways: GHS-R1a drives Gq/11, PLC, IP3, and calcium release, while GHRH raises cAMP. Combining them typically produces amplified GH secretion exceeding either agonist alone, a complementary mechanism researchers exploit to probe pituitary signaling.
What Analytical Methods Verify Ipamorelin Peptide Purity and Identity?
Researchers typically verify ipamorelin’s purity and identity using reversed-phase HPLC to quantify purity and detect impurities, paired with mass spectrometry (ESI-MS or MALDI-TOF) to confirm the pentapeptide’s molecular weight and sequence identity. Researchers can add amino acid analysis to check composition, and NMR to confirm structure. For sequence verification, researchers run tandem MS/MS fragmentation. Together, these methods confirm researchers have the correct Aib-His-D-2-Nal-D-Phe-Lys-NH₂ sequence at high purity.
